Last reviewed · How we verify
Posaconazole oral suspension
Posaconazole oral suspension is a Triazole antifungal Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Prophylaxis of invasive Aspergillus and Candida infections in high-risk immunocompromised patients, Treatment of oropharyngeal candidiasis, Treatment of invasive fungal infections in immunocompromised patients. Also known as: MK-5592, SCH 056592, Noxafil®.
Posaconazole inhibits fungal cell membrane ergosterol synthesis by blocking lanosterol 14α-demethylase, disrupting fungal cell wall integrity.
Posaconazole inhibits fungal cell membrane ergosterol synthesis by blocking lanosterol 14α-demethylase, disrupting fungal cell wall integrity. Used for Prophylaxis of invasive Aspergillus and Candida infections in high-risk immunocompromised patients, Treatment of oropharyngeal candidiasis, Treatment of invasive fungal infections in immunocompromised patients.
At a glance
| Generic name | Posaconazole oral suspension |
|---|---|
| Also known as | MK-5592, SCH 056592, Noxafil® |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Triazole antifungal |
| Target | Lanosterol 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
As a triazole antifungal, posaconazole binds to the cytochrome P450-dependent enzyme lanosterol 14α-demethylase in fungi, preventing the conversion of lanosterol to ergosterol. This disrupts the fungal cell membrane structure, leading to cell lysis and fungal death. The oral suspension formulation provides improved bioavailability compared to earlier formulations.
Approved indications
- Prophylaxis of invasive Aspergillus and Candida infections in high-risk immunocompromised patients
- Treatment of oropharyngeal candidiasis
- Treatment of invasive fungal infections in immunocompromised patients
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Abdominal pain
- Elevated liver enzymes
- Hypokalemia
Key clinical trials
- Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease (PHASE2)
- Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127) (PHASE2)
- Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis
- Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia (PHASE1, PHASE2)
- A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection (PHASE2, PHASE3)
- Pharmacokinetics of Posaconazole in Children With Chronic Granulomatous Disease (CGD) (PHASE2)
- Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120) (PHASE1)
- Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Posaconazole oral suspension CI brief — competitive landscape report
- Posaconazole oral suspension updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Posaconazole oral suspension
What is Posaconazole oral suspension?
How does Posaconazole oral suspension work?
What is Posaconazole oral suspension used for?
Who makes Posaconazole oral suspension?
Is Posaconazole oral suspension also known as anything else?
What drug class is Posaconazole oral suspension in?
What development phase is Posaconazole oral suspension in?
What are the side effects of Posaconazole oral suspension?
What does Posaconazole oral suspension target?
Related
- Drug class: All Triazole antifungal drugs
- Target: All drugs targeting Lanosterol 14α-demethylase (CYP51)
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Prophylaxis of invasive Aspergillus and Candida infections in high-risk immunocompromised patients
- Indication: Drugs for Treatment of oropharyngeal candidiasis
- Indication: Drugs for Treatment of invasive fungal infections in immunocompromised patients
- Also known as: MK-5592, SCH 056592, Noxafil®
- Compare: Posaconazole oral suspension vs similar drugs
- Pricing: Posaconazole oral suspension cost, discount & access